Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin antagonists.

A Benigni1, G Remuzzi

  • 1Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

Lancet (London, England)
|February 19, 1999
PubMed
Summary
This summary is machine-generated.

Endothelin antagonists show promise for cardiovascular and renal diseases. Further research is needed to confirm efficacy and safety compared to existing treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AAV9-mediated engineering of autotransplanted kidney of non-human primates.

Gene therapy·2017
Same author

Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.

Gene therapy·2016
Same author

Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.

Gene therapy·2016
Same author

Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy.

Minerva anestesiologica·2015
Same author

An unanticipated role for survivin in organ transplant damage.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Endothelin, a potent vasoconstrictor, has three isoforms and two receptor subtypes (A and B).
  • Various endothelin antagonists, selective and non-selective, have been developed.
  • Current applications are primarily experimental, aiding in understanding cardiovascular and renal disease mechanisms.

Purpose of the Study:

  • To review the potential clinical applications of endothelin antagonists.
  • To discuss the evidence supporting their use in cardiovascular and renal conditions.
  • To identify challenges and concerns regarding their clinical implementation.

Main Methods:

  • Review of preclinical studies and clinical investigations of endothelin antagonists.
  • Analysis of data from healthy volunteers and patient studies.

Related Experiment Videos

  • Synthesis of evidence regarding efficacy and safety profiles.

    • Main Results:

    • Endothelin antagonists show potential in treating hypertension, cerebrovascular damage, and heart failure.
    • Renal applications are also being explored.
    • Limited clinical data exists, primarily from non-selective antagonist bosentan and other agents.

    Conclusions:

    • Endothelin antagonists represent a promising therapeutic avenue for cardiovascular and renal diseases.
    • Demonstrating superiority over existing drugs is crucial for clinical adoption.
    • Potential risks include conflicting actions with mixed antagonists and developmental toxicity observed in animal studies.